



INVESTIGADOR AECC Adjudicatarios

**Dr. Oscar Molina Campoy**

Instituto de Investigación Contra
la Leucèmia Josep Carreras (IJC), Barcelona

Contribution of chromosome instability to the outcome of
aneuploid childhood B-cell acute lymphoblastic leukemia

Dra. Esperanza Martín Sánchez

Clínica Universidad de Navarra, Navarra

Single-cell immunophenotypic and transcriptomic profiling
for minimally-invasive detection of early multiple myeloma

Dr. José Alberto López Domínguez

IRB Barcelona, Barcelona

Role of PD-L2 in cancer relapse after chemotherapy-
induced senescence

Dr. Pau Francesc Pascual García

Centro de Regulación Genómica (CRG),
Barcelona

Functional characterization of diffuse intrinsic
pontine glioma

Dra. Fara Brasó Maristany

Fundació Privada Clínic per a la Recerca
Biomèdica, Barcelona

Identification and validation of therapeutic targets
to overcome resistance to CDK4/6 inhibitors in metastatic
hormone receptor-positive HER2-negative breast cancer

Dra. Fernanda da Silva Andrade

Instituto de Recerca Hospital Universitario Vall
d'Hebron (VHIR), Barcelona

Design of Nanoparticles for Blood-Brain-Barrier Crossing
and Glioblastoma Multiforme Cancer Stem Cells
Targeting (NanoGlio)

Dra. Pilar Villacampa Alcubierre

Instituto de Investigación Contra
la Leucèmia Josep Carreras (IJC), Barcelona

Mapping stromal molecular programs that
govern tumour aggressiveness in Prostate Cancer

Dra. Inmaculada Conejos Sánchez

Centro de Investigación Príncipe Felipe,
Valencia

Polymer Therapeutics for pediatric solid tumors (PT4PST)

Dra. Clotilde Costa Noguera

Instituto de Investigación Sanitaria de Santiago
(IDIS-CHUS), A Coruña

Identification of biomarkers of response and resistance in
the blood to combined therapy of CDK4/6 inhibitors and
endocrine therapy in patients with metastatic luminal
breast cancer (IBLUCA)



INVESTIGADOR AECC Suplentes



Dra. Isabel Puig Borreil

Vall d'Hebron Instituto de Oncología (VHIO),
Barcelona

Deciphering the molecular mechanisms of
tumour cell resistance to cancer therapies

Dra. Karmele Valencia Leoz

Cima Universidad de Navarra, Navarra

DSTYK: a dual serine/ threonine and tyrosine kinase as
a new tool for lung cáncer treatment

Dra. María Araceli Gago Arias

Instituto de Investigación Sanitaria de Santiago
(IDIS-CHUS), A Coruña

Personalized treatment planning in
molecular radiotherapy: individualized dosimetry
and radiobiological assessment

Dr. Néstor García Rodríguez

Centro Andaluz de Biología Molecular y
Medicina regenerativa (CABIMER-CSIC),
Sevilla

Sensing and dealing with DNA damage during
replication as a critical barrier for carcinogenesis

Dra. Marta Montes Resano

Cima Universidad de Navarra, Navarra

Identification and characterisation of therapy-
induced senescence associated long non-coding RNAs
as new candidates for lung cancer treatment